Company news

Arcturus Therapeutics Holdings Inc. news in 2024

Arcturus Therapeutics Holdings Inc.'s news releases, calls and decks from 2024, newest first.

View company

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 15, 2024

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

November 17, 2024

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

November 10, 2024

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

November 6, 2024

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

October 30, 2024

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

September 29, 2024

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

September 12, 2024

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

September 2, 2024

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

August 26, 2024

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

August 4, 2024

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

July 31, 2024

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

July 17, 2024

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

June 30, 2024

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

June 19, 2024

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

June 6, 2024

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

May 27, 2024

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

May 19, 2024

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine

May 19, 2024

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

May 7, 2024

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

April 24, 2024

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

March 6, 2024

Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

February 25, 2024

Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

February 21, 2024

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024

February 19, 2024

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

February 4, 2024

PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems

January 4, 2024

Calls in 2024

Decks in 2024